Medicine and Health Sciences Commons^™

A Novel Design Of A Phase Iii Trial Of Isradipine In Early Parkinson Disease (Steady-Pd Iii), Kevin M. Biglan, David Oakes, Anthony E. Lang, Robert A. Hauser, Karen Hodgeman, Brittany Greco, Jillian Lowell, Rebecca Rockhill, Ira Shoulson, Charles Venuto, Diony Young, Tanya Simuni

Neurology Faculty Publications

Objectives To describe the rationale for a novel study design and baseline characteristics of a disease-modifying trial of isradipine 10 mg daily in early Parkinson disease (PD).

Methods STEADY-PDIII is a 36-month, Phase 3, parallel group, placebo-controlled study of the efficacy of isradipine 10 mg daily in 336 participants with early PD as measured by the change in the Unified Parkinson Disease Rating Scale (UPDRS) Part I-III score in the practically defined ON state. Secondary outcome measures include clinically meaningful measures of disability progression in early PD: (1) Time to initiation and utilization of dopaminergic therapy; (2) Time to onset …

Carotid Endarterectomy In A Patient With Severe Internal Carotid Artery Stenosis With Persistent Trigeminal Artery And Ischemia Of The Anterior And Posterior Circulation, Melanie R. F. Greenway, Hussam A. Yacoub, Shweta Varade, Yevgeniy Isayev

Neurology Faculty Publications

Occurrence of cerebral ischemia in the posterior circulation as a result of severe internal carotid artery disease and persistent trigeminal artery is rare. An 81-year-old man with medical history of hypertension and ischemic stroke presented with dizziness, nausea, and mild dysarthria. Magnetic resonance imaging of the brain revealed acute infarcts in the left internal carotid artery territory. CT angiogram revealed a persistent trigeminal artery (PTA) and severe atherosclerosis. The patient developed new neurological symptoms and repeat imaging revealed new acute infarcts in the PTA distribution. After undergoing a left carotid endarterectomy with no complications, the patient was discharged to a …

Impact Of Diabetes In The Friedreich Ataxia Clinical Outcome Measures Study, Ashley Mccormick, Jennifer Farmer, Susan Perlman, Martin Delatycki, George Wilmot, Katherine Matthews, Grace Yoon, Chad Hoyle, Sub H. Subramony, Theresa Zesiewicz, David R. Lynch, Shana E. Mccormack

Neurology Faculty Publications

Objective Friedreich ataxia (FA) is a progressive neuromuscular disorder caused by GAA triplet repeat expansions or point mutations in the FXN gene. FA is associated with increased risk of diabetes mellitus (DM). This study assessed the age-specific prevalence of FA-associated DM and its impact on neurologic outcomes.

Research Design and Methods Participants were 811 individuals with FA from 12 international sites in a prospective natural history study (FA Clinical Outcome Measures Study, FACOMS). Physical function was assessed, using validated instruments. Multivariable regression analyses examined the independent association of DM with outcomes.

Results Mean age of participants was 30.1 years (SD …

Racial‐Ethnic Disparities In Acute Stroke Care In The Florida‐Puerto Rico Collaboration To Reduce Stroke Disparities Study, Ralph L. Sacco, Hannah Gardener, Kefeng Wang, Chuanhui Dong, Maria A. Ciliberti-Vargas, Carolina M. Gutierrez, Negar Asdaghi, W. Scott Burgin, Olveen Carrasquillo, Enid J. Garcia-Rivera, Ulises Nobo, Sofia Oluwole, David Z. Rose, Michael F. Waters, Juan Carlos Zevallos, Mary Robichaux, Salina P. Waddy, Jose G. Romano, Tatjana Rundek

Neurology Faculty Publications

Background: Racial‐ethnic disparities in acute stroke care can contribute to inequality in stroke outcomes. We examined race‐ethnic disparities in acute stroke performance metrics in a voluntary stroke registry among Florida and Puerto Rico Get With the Guidelines‐Stroke hospitals.

Methods and Results: Seventy‐five sites in the Florida Puerto Rico Stroke Registry (66 Florida and 9 Puerto Rico) recorded 58 864 ischemic stroke cases (2010–2014). Logistic regression models examined racial‐ethnic differences in acute stroke performance measures and defect‐free care (intravenous tissue plasminogen activator treatment, in‐hospital antithrombotic therapy, deep vein thrombosis prophylaxis, discharge antithrombotic therapy, appropriate anticoagulation therapy, statin use, smoking cessation counseling) …

Serotonin Syndrome Complicating Treatment Of Ifosfamide Neurotoxicity With Methylene Blue, Matthew Snyder, Suhas Gangadhara, Andrew S. Brohl, Steven Ludlow, Sowmya Nanjappa

Neurology Faculty Publications

Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings. Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity, as there is significant clinical overlap between these 2 syndromes. Practitioners must remain vigilant of this potential life-threatening complication in this …

Incidence Of Seizure Exacerbation And Seizures Reported As Adverse Events During Adjunctive Treatment With Eslicarbazepine Acetate: A Pooled Analysis Of Three Phase Iii Controlled Trials, Mar Carreño, Selim Benbadis, Francisco Rocha, David Blum, Hailong Cheng

Neurology Faculty Publications

No abstract provided.